A phase II study of DFP-14323, a non-specific immunomodulator, in combination with low-dose afatinib as first-line therapy for common EGFR mutation-positive NSCLC - Hiroshige Yoshioka; Masahide Mori; Nobuyuki Katakami; Toshihide Yokoyama; Hiroyasu Kaneda; Hirotaka Matsumoto; Motohiro Tamiya; Kouji Yamamoto; Cheng-long Huang (Therapeutic Advances in Medical Oncology, 2026)